Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-07-01-Speech-2-155"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2003-07-01"^^xsd:date2
dcterms:Is Part Of	lp_eu:Strengthening the European pharmaceutical industry in the interest of patients – proposals for action2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20030701.6.2-155"2
lpv:hasSubsequent	lp_eu:2003-07-01-Speech-2-1562
lpv:speaker	lp:Dorette Corbey2
lpv:spokenAs	substitute; Delegation to the EU-Turkey Joint Parliamentary Committee (2002-02-07--2004-07-19)3 unknown; Partij van de Arbeid (1999-07-20--2004-07-19)3 substitute; Committee on Industry, External Trade, Research and Energy (2002-01-17--2004-07-19)3 member; PES (1999-07-20--2004-07-19)3 member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3
lpv:translated text	"Mr President, Commissioner, the pharmaceutical industry is not doing all that well. There is a lack of innovation. That is why there is the temptation to provide better protection for existing products or produce minor variations on them, and prices remain unacceptably high. Your communication is therefore very well-timed. You were both right in saying that the patient must be placed at the centre of the debate, but the question is, of course, who that patient is. As one of the previous speakers already remarked, patients in developing countries are still faced with a shortage of medicines. In actual fact, no, or hardly any, research is being done into diseases of the developing countries. I would therefore want to ask you what initiatives you intend to take in order to give research into the neglected diseases a shot in the arm, so much so that the pharmaceutical industry as a whole will also enjoy the benefits."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph